Transgene SA (TNG.PA)
EUR 0.71
(-1.8%)
EUR 0.71
(-1.8%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 45.21 Million EUR | -31.94% |
| 2022 | 66.43 Million EUR | -34.76% |
| 2021 | 101.83 Million EUR | 19.17% |
| 2020 | 85.45 Million EUR | -26.0% |
| 2019 | 115.47 Million EUR | 6.39% |
| 2018 | 108.54 Million EUR | 7.6% |
| 2017 | 100.87 Million EUR | -17.96% |
| 2016 | 122.95 Million EUR | 21.89% |
| 2015 | 100.86 Million EUR | -28.44% |
| 2014 | 140.95 Million EUR | 12.0% |
| 2013 | 125.85 Million EUR | -21.57% |
| 2012 | 160.46 Million EUR | -17.11% |
| 2011 | 193.58 Million EUR | -13.46% |
| 2010 | 223.68 Million EUR | 126.72% |
| 2009 | 98.66 Million EUR | -22.1% |
| 2008 | 126.64 Million EUR | -1.3% |
| 2007 | 128.31 Million EUR | 293.54% |
| 2006 | 32.6 Million EUR | 0.0% |
| 2004 | 25.5 Million EUR | -44.34% |
| 2003 | 45.81 Million EUR | -31.49% |
| 2002 | 66.88 Million EUR | -22.61% |
| 2001 | 86.41 Million EUR | 80.27% |
| 2000 | 47.93 Million EUR | -28.33% |
| 1999 | 66.88 Million EUR | -21.14% |
| 1998 | 84.81 Million EUR | 181.28% |
| 1997 | 30.15 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 50.75 Million EUR | 0.0% |
| 2023 Q1 | 49.55 Million EUR | -25.42% |
| 2023 Q4 | 45.21 Million EUR | 0.0% |
| 2023 Q2 | 49.55 Million EUR | 0.0% |
| 2023 Q3 | 45.21 Million EUR | -8.74% |
| 2023 FY | 45.21 Million EUR | -31.94% |
| 2022 Q3 | 66.43 Million EUR | -22.5% |
| 2022 FY | 66.43 Million EUR | -34.76% |
| 2022 Q4 | 66.43 Million EUR | 0.0% |
| 2022 Q2 | 85.72 Million EUR | 0.0% |
| 2022 Q1 | 85.72 Million EUR | -15.83% |
| 2021 Q2 | 106.92 Million EUR | 0.0% |
| 2021 FY | 101.83 Million EUR | 19.17% |
| 2021 Q1 | 106.92 Million EUR | 25.12% |
| 2021 Q3 | 101.83 Million EUR | -4.75% |
| 2021 Q4 | 101.83 Million EUR | 0.0% |
| 2020 Q1 | 109.76 Million EUR | -4.94% |
| 2020 Q2 | 109.76 Million EUR | 0.0% |
| 2020 Q3 | 85.45 Million EUR | -22.15% |
| 2020 FY | 85.45 Million EUR | -26.0% |
| 2020 Q4 | 85.45 Million EUR | 0.0% |
| 2019 Q2 | 93.82 Million EUR | 0.0% |
| 2019 FY | 115.47 Million EUR | 6.39% |
| 2019 Q3 | 115.47 Million EUR | 23.08% |
| 2019 Q4 | 115.47 Million EUR | 0.0% |
| 2019 Q1 | 93.82 Million EUR | -13.56% |
| 2018 FY | 108.54 Million EUR | 7.6% |
| 2018 Q2 | 85.12 Million EUR | 0.0% |
| 2018 Q1 | 85.12 Million EUR | -15.61% |
| 2018 Q4 | 108.54 Million EUR | -0.1% |
| 2018 Q3 | 108.64 Million EUR | 27.63% |
| 2017 Q4 | 100.87 Million EUR | 0.0% |
| 2017 Q2 | 101.86 Million EUR | 0.0% |
| 2017 FY | 100.87 Million EUR | -17.96% |
| 2017 Q3 | 100.87 Million EUR | -0.98% |
| 2017 Q1 | 101.86 Million EUR | -17.15% |
| 2016 FY | 122.95 Million EUR | 21.89% |
| 2016 Q3 | 122.95 Million EUR | 30.08% |
| 2016 Q2 | 94.51 Million EUR | 0.0% |
| 2016 Q1 | 94.51 Million EUR | -6.3% |
| 2016 Q4 | 122.95 Million EUR | 0.0% |
| 2015 Q2 | 128.31 Million EUR | 0.0% |
| 2015 FY | 100.86 Million EUR | -28.44% |
| 2015 Q4 | 100.86 Million EUR | 0.0% |
| 2015 Q3 | 100.86 Million EUR | -21.39% |
| 2015 Q1 | 128.31 Million EUR | -8.97% |
| 2014 Q4 | 140.95 Million EUR | 0.0% |
| 2014 Q3 | 140.95 Million EUR | -20.11% |
| 2014 FY | 140.95 Million EUR | 12.0% |
| 2014 Q2 | 176.42 Million EUR | 0.0% |
| 2014 Q1 | 176.42 Million EUR | 40.19% |
| 2013 Q1 | 143.69 Million EUR | -10.45% |
| 2013 FY | 125.85 Million EUR | -21.57% |
| 2013 Q4 | 125.85 Million EUR | 0.0% |
| 2013 Q3 | 125.85 Million EUR | -12.42% |
| 2013 Q2 | 143.69 Million EUR | 0.0% |
| 2012 FY | 160.46 Million EUR | -17.11% |
| 2012 Q4 | 160.46 Million EUR | 0.0% |
| 2012 Q2 | 181.18 Million EUR | 0.0% |
| 2012 Q3 | 160.46 Million EUR | -11.44% |
| 2011 Q2 | 211.93 Million EUR | 0.0% |
| 2011 Q4 | 193.58 Million EUR | 0.0% |
| 2011 FY | 193.58 Million EUR | -13.46% |
| 2010 FY | 223.68 Million EUR | 126.72% |
| 2010 Q2 | 239.33 Million EUR | 0.0% |
| 2010 Q4 | 223.68 Million EUR | 0.0% |
| 2009 Q2 | 111.91 Million EUR | 0.0% |
| 2009 FY | 98.66 Million EUR | -22.1% |
| 2009 Q4 | 98.66 Million EUR | 0.0% |
| 2008 FY | 126.64 Million EUR | -1.3% |
| 2008 Q4 | 126.64 Million EUR | 0.0% |
| 2007 FY | 128.31 Million EUR | 293.54% |
| 2006 FY | 32.6 Million EUR | 0.0% |
| 2005 Q2 | 15.14 Million EUR | 0.0% |
| 2004 FY | 25.5 Million EUR | -44.34% |
| 2004 Q4 | 25.5 Million EUR | 0.0% |
| 2004 Q2 | 34.8 Million EUR | -13.33% |
| 2004 Q1 | 40.15 Million EUR | -12.36% |
| 2003 Q3 | 51.36 Million EUR | -8.84% |
| 2003 Q4 | 45.81 Million EUR | -10.8% |
| 2003 Q2 | 56.34 Million EUR | -7.98% |
| 2003 FY | 45.81 Million EUR | -31.49% |
| 2003 Q1 | 61.23 Million EUR | -8.44% |
| 2002 Q4 | 66.88 Million EUR | -4.8% |
| 2002 Q2 | 75.54 Million EUR | -6.01% |
| 2002 Q1 | 80.36 Million EUR | -7.0% |
| 2002 FY | 66.88 Million EUR | -22.61% |
| 2002 Q3 | 70.25 Million EUR | -7.0% |
| 2001 Q3 | 92.48 Million EUR | -6.67% |
| 2001 Q4 | 86.41 Million EUR | -6.56% |
| 2001 FY | 86.41 Million EUR | 80.27% |
| 2001 Q1 | 41.82 Million EUR | -12.75% |
| 2001 Q2 | 99.09 Million EUR | 136.94% |
| 2000 Q1 | 61.23 Million EUR | -8.45% |
| 2000 FY | 47.93 Million EUR | -28.33% |
| 2000 Q3 | 51.39 Million EUR | -12.34% |
| 2000 Q4 | 47.93 Million EUR | -6.72% |
| 2000 Q2 | 58.62 Million EUR | -4.26% |
| 1999 FY | 66.88 Million EUR | -21.14% |
| 1999 Q4 | 66.88 Million EUR | 0.0% |
| 1998 FY | 84.81 Million EUR | 181.28% |
| 1998 Q4 | 84.81 Million EUR | 0.0% |
| 1997 FY | 30.15 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -207.39% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 86.175% |
| Adocia SA | 24.95 Million EUR | -81.187% |
| Aelis Farma SA | 26.28 Million EUR | -72.052% |
| Biophytis S.A. | 11.93 Million EUR | -278.829% |
| Advicenne S.A. | 12.4 Million EUR | -264.447% |
| genOway Société anonyme | 31.84 Million EUR | -42.003% |
| IntegraGen SA | 8 Million EUR | -465.188% |
| Medesis Pharma S.A. | 1.92 Million EUR | -2247.307% |
| Neovacs S.A. | 47.53 Million EUR | 4.874% |
| NFL Biosciences SA | 3.97 Million EUR | -1038.787% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -203.207% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -1106.826% |
| Sensorion SA | 46.49 Million EUR | 2.747% |
| Theranexus Société Anonyme | 7.23 Million EUR | -524.739% |
| TME Pharma N.V. | 2.49 Million EUR | -1715.215% |
| Valbiotis SA | 33.24 Million EUR | -35.999% |
| TheraVet SA | 7.53 Million EUR | -500.157% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -28.188% |
| argenx SE | 4.11 Billion EUR | 98.9% |
| BioSenic S.A. | 9.55 Million EUR | -373.031% |
| Celyad Oncology SA | 16.28 Million EUR | -177.712% |
| DBV Technologies S.A. | 165.65 Million USD | 72.703% |
| Galapagos NV | 4.35 Billion EUR | 98.962% |
| Genfit S.A. | 173.87 Million EUR | 73.994% |
| GeNeuro SA | 6.31 Million EUR | -616.264% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 5.168% |
| Innate Pharma S.A. | 184.19 Million EUR | 75.451% |
| Inventiva S.A. | 69.13 Million EUR | 34.6% |
| MaaT Pharma SA | 42.93 Million EUR | -5.325% |
| MedinCell S.A. | 36.94 Million EUR | -22.38% |
| Nanobiotix S.A. | 93.89 Million EUR | 51.844% |
| Onward Medical N.V. | 43.62 Million EUR | -3.64% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 57.702% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 44.79% |
| Oxurion NV | 6.55 Million EUR | -590.336% |
| Pharming Group N.V. | 426.33 Million EUR | 89.394% |
| Poxel S.A. | 4.82 Million EUR | -837.529% |
| GenSight Biologics S.A. | 9.08 Million EUR | -397.601% |
| Financière de Tubize SA | 1.92 Billion EUR | 97.645% |
| UCB SA | 15.53 Billion EUR | 99.709% |
| Valneva SE | 469.39 Million EUR | 90.367% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -46.67% |